Eli Lilly’s strong sales momentum carried over into the final quarter of 2025, and it’s set to do the same this year.
Eli Lilly’s fourth-quarter revenue grew 43% to $19.3bn (consensus $18.0bn) driven by volume growth in its best sellers, Mounjaro and Zepbound.
Underlying operating profit was up 52% to $8.6bn as revenue growth outpaced cost expansion.
2026 sales are expected land in the $80bn-$83bn range, reflecting growth of 25% at the mid-point and better than consensus forecasts. Underlying earnings per share guidance stands at $33.50-$35.00, implying growth of about 41%.
The shares rose 7.8% in early trading.
